click below
click below
Normal Size Small Size show me how
A&P Lecture 11
| Question | Answer |
|---|---|
| Incretins are | metabolic hormones released from the gut after eating |
| Examples of incretins include | Glucagon-like peptide (GLP-1) Gastric inhibitory polypeptide (GIP) |
| What cell produces Incretins? | Enteroendocrine cells (specifically L-cells for GLP-1) in the small intestine + colon secrete these hormones |
| Stimulus for incretin release | Macromolecules- primarily carbohydrates, lipids, and proteins + gastric distension |
| Targets and effects for incretins Pancreas | increase insulin and decrease glucagon secretion |
| Targets and effects for incretins Gastrointestinal tract | decrease gastric emptying (this increases nutrient absorption) |
| Targets and effects for incretins Brain (spec- hypothalamus) | reduces appetite and increases satiety (feeling full) |
| Incretins prepare the body for incoming nutrients by coordinating insulin release, sowing digestion, and reducing appetite | |
| GLP-1 has a very WHAT life span | short! 1-2 mins |
| Why is GLP-1 life span so short? | GLP 1 is rapidly broken down by the enzyme DPP-4 (dipeptidyl peptidase-4) DDP-4 is widely expressed by cells and can be soluble or membrane bound |
| The gila monster | The gila monster has a unique life style Eats infrequently (sometimes only a few times a year) Must store and regulate nutrients efficiently |
| Reptile venom and saliva are rich in | Peptides Enzymes Signaling molecules PES |
| These compounds (PES) often | Act on specific receptors Have strong physiological effects |
| Exdenin-4 | Was discovered in the 1990s in the saliva of the gila monster It mimics human GLP-1 but is resistant to rapid breakdown (DPP-4), giving it a much longer lifespan *This discovery led to GLP-1 receptor agonist drugs used to treat diabetes and obesity* |
| Most GLP-1 receptors agonists end with what? Which refers to what? | -glutide, this refers to the fact these drugs are proteins that mimics glucose-like peptide |
| These drugs are modified versions of | endogenous GLP-1 that are resistant to DPP-4 breakdown, allowing them to last longer in the body |
| First GLP-1 RA: Exenatide (byetta) | FDA approved in 2005 Derived from extendin-4 (the gila monster saliva) Initially used to treat type 2 diabetes |
| Goals of GLP-1 RA Exenatide (byetta) | Improved blood glucose control Lower risk of hypoglycemia compared to insulin Insulin carries the risk of lowering blood glucose to dangerous levels |
| Results of GLP-1 RA Exenatide (byetta) | Patients were found to exhibit reduced blood glucose levels!! Weight loss- patients lost 15% of their body compared to 2% in placebo controls |
| Why does this matter? | Improved body weight regulation - Reduces insulin resistance, inflammation, and metabolic stress - Lower risk of cardiovascular and fatty liver disease - Improves mobility, energy, and metabolic health |
| Improved glycemic control | Lower HbA1c = better long-term blood glucose control Reduced risk of: - Neuropathy - Retinopathy - Kidney disease |
| Results of the GLP-1 RA | Decreased complications Increase quality of life Increase life expectancy |
| Why GLP-1 RA are a public health game changer | GLP-1 drugs target two of the most common and costly diseases in the U.S: obesity and type 2 diabetes As of 2022-2023, approximately 42% of U.S adults are obese 1 in 8 Americans are living with diabetes (95% are type 2) |
| These two disorders are estimated to cost the US over 2 trillion a year So yeah. curing diabetes is a good thing | |
| Beneficial findings Clinically significant weight loss (10-20% body weight in many patients0 ~20% reduction in risk of major adverse cardiovascular events High risk patients ~19% decrease in end stage kidney disease | |
| Small study- slightly reduced risk of blood cancer Reduced insulin resistance Reduced blood glucose levels | |
| A meta analysis | statistical method that combines data from multiple independent studies addressing the same research question |
| Side effects of GLP-1s | Most common = GI issues (nausea, diarrhea, vomiting) Common = reduced bone density, increased risk for fracture Common = mouscle loss (as high as ⅓ of weight loss is muscle) Rare but severe = pancreatitis, gall stones, thyroid tumors |
| Limitations: | Many positive effects are lost when stopping GLP1s (weight and CV protection) Expensive, not always covered by insurance Unknown long-term consequences |
| Future directions Combination treatment- to improve efficacy and reduce side effects Improve dosage with expanded use Improving understanding of side effects Reducing costs and improving access |